Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

Published:2019-09-11 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Lu Jun,Shi Qin,Zhang Lele,Wu Jun,Lou Yuqing,Qian Jie,Zhang Bo,Wang Shuyuan,Wang Huimin,Zhao Xiaodong,Han Baohui

Funder

School of Medicine, Shanghai Jiao Tong University

Science and Technology Commission of Shanghai Municipality

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference40 articles.

1. Biomarkers for personalized oncology: recent advances and future challenges;Kalia;Metabolism.,2015

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science.,2004

3. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med.,2014

4. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol.,2012

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet.,2016

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis;2024-02-14

2. Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer;Medical Oncology;2023-07-05

3. Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients;Biomarker Research;2022-07-29

4. Screening anlotinib responders via blood‐based proteomics in non‐small cell lung cancer;The FASEB Journal;2022-07-22

5. Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis;International Journal of Pharmaceutics;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3